| A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer J Hynninen, J Kemppainen, M Lavonius, J Virtanen, J Matomäki, S Oksa, ... Gynecologic oncology 131 (2), 389-394, 2013 | 122 | 2013 |
| FDG PET/CT in staging of advanced epithelial ovarian cancer: frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread J Hynninen, A Auranen, O Carpén, K Dean, M Seppänen, J Kemppainen, ... Gynecologic oncology 126 (1), 64-68, 2012 | 114 | 2012 |
| Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy? J Hynninen, M Lavonius, S Oksa, S Grénman, O Carpén, A Auranen Gynecologic oncology 128 (2), 229-232, 2013 | 107 | 2013 |
| A functional homologous recombination assay predicts primary chemotherapy response and long-term survival in ovarian cancer patients M Tumiati, S Hietanen, J Hynninen, E Pietilä, A Färkkilä, K Kaipio, ... Clinical Cancer Research 24 (18), 4482-4493, 2018 | 101 | 2018 |
| Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance EA Pietilä, J Gonzalez-Molina, L Moyano-Galceran, S Jamalzadeh, ... Nature communications 12 (1), 3904, 2021 | 87 | 2021 |
| Genetically defined syngeneic mouse models of ovarian cancer as tools for the discovery of combination immunotherapy S Iyer, S Zhang, S Yucel, H Horn, SG Smith, F Reinhardt, E Hoefsmit, ... Cancer Discovery 11 (2), 384-407, 2021 | 78 | 2021 |
| Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer K Zhang, EP Erkan, S Jamalzadeh, J Dai, N Andersson, K Kaipio, ... Science advances 8 (8), eabm1831, 2022 | 76 | 2022 |
| Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer T Vallius, J Hynninen, A Auranen, O Carpén, J Matomäki, S Oksa, ... Tumor Biology 35, 12389-12395, 2014 | 70 | 2014 |
| 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer T Vallius, A Peter, A Auranen, O Carpén, J Kemppainen, J Matomäki, ... Gynecologic oncology 140 (1), 29-35, 2016 | 51 | 2016 |
| PET/CT for evaluation of ovarian cancer J Kemppainen, J Hynninen, J Virtanen, M Seppänen Seminars in nuclear medicine 49 (6), 484-492, 2019 | 50 | 2019 |
| ALDH1A1‐related stemness in high‐grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR‐PI3K/aurora kinase inhibitors K Kaipio, P Chen, P Roering, K Huhtinen, P Mikkonen, P Östling, ... The Journal of pathology 250 (2), 159-169, 2020 | 41 | 2020 |
| Serum HE4 profile during primary chemotherapy of epithelial ovarian cancer J Hynninen, A Auranen, K Dean, M Lavonius, O Carpen, A Perheentupa, ... International Journal of Gynecologic Cancer 21 (9), 2011 | 41 | 2011 |
| Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Müllerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors UM Haltia, M Hallamaa, J Tapper, J Hynninen, H Alfthan, B Kalra, ... Gynecologic Oncology 144 (1), 83-89, 2017 | 40 | 2017 |
| Identification of prognostic groups in high-grade serous ovarian cancer treated with platinum–taxane chemotherapy P Chen, K Huhtinen, K Kaipio, P Mikkonen, V Aittomäki, R Lindell, ... Cancer research 75 (15), 2987-2998, 2015 | 39 | 2015 |
| Mathematical modeling predicts response to chemotherapy and drug combinations in ovarian cancer E Kozłowska, A Färkkilä, T Vallius, O Carpén, J Kemppainen, S Grénman, ... Cancer research 78 (14), 4036-4044, 2018 | 38 | 2018 |
| 18F-FDG-PET/CT based total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer T Vallius, J Hynninen, J Kemppainen, V Alves, K Auranen, J Matomäki, ... European journal of nuclear medicine and molecular imaging 45, 1224-1232, 2018 | 36 | 2018 |
| Prospective longitudinal ctDNA workflow reveals clinically actionable alterations in ovarian cancer J Oikkonen, K Zhang, L Salminen, I Schulman, K Lavikka, N Andersson, ... JCO Precision Oncology 3, 1-12, 2019 | 31 | 2019 |
| A nanoparticle-lectin immunoassay improves discrimination of serum CA125 from malignant and benign sources K Gidwani, K Huhtinen, H Kekki, S van Vliet, J Hynninen, N Koivuviita, ... Clinical Chemistry 62 (10), 1390-1400, 2016 | 30 | 2016 |
| Glycovariant-based lateral flow immunoassay to detect ovarian cancer–associated serum CA125 S Bayoumy, H Hyytiä, J Leivo, SM Talha, K Huhtinen, M Poutanen, ... Communications biology 3 (1), 460, 2020 | 26 | 2020 |
| A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer L Salminen, N Nadeem, S Jain, S Grènman, O Carpén, S Hietanen, ... Gynecologic Oncology 156 (3), 689-694, 2020 | 25 | 2020 |
Sampsa HautaniemiProfessor of systems biology, Faculty of Medicine, University of HelsinkiVerified email at helsinki.fi
